GoodRx Q2 2025 Financial Results

GoodRx Holdings, Inc., a leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. The company reported revenue and adjusted EBITDA margin in line with previous guidance, with notable growth in its Pharma Manufacturer Solutions segment.

Financial Highlights

For the second quarter of 2025, GoodRx reported:

• Revenue of $203.1 million, a 1% increase from $200.6 million in the same period last year.
• Net income of $12.8 million, up from $6.7 million, with a net income margin of 6.3% compared to 3.3%.
• Adjusted Net Income of $33.9 million, with an adjusted net income margin of 16.7%.
• Adjusted EBITDA of $69.4 million, with an adjusted EBITDA margin of 34.2%.
• Net cash provided by operating activities of $49.6 million, a significant increase from $9.7 million in the comparable period last year.

Business and Operational Highlights

GoodRx experienced a 32% year-over-year increase in Pharma Manufacturer Solutions revenue, reaching $35.0 million. This growth was driven by organic expansion and increased market penetration with pharmaceutical manufacturers and other customers. However, the company saw a 3% decrease in prescription transactions revenue and a 7% decrease in subscription revenue, primarily due to broader changes in the retail pharmacy landscape and a reduction in the number of subscription plans.

Strategic Initiatives and Corporate Developments

During the second quarter, GoodRx repurchased 10.2 million shares of Class A common stock for an aggregate of $46.4 million. As of June 30, 2025, the company had $143.0 million of unused authorized share repurchase capacity under its $450.0 million share repurchase program. The company remains focused on a disciplined approach to capital allocation, prioritizing investments for profitable growth, debt reduction, share buybacks, and strategic M&A activities.

Management's Perspective

Wendy Barnes, Chief Executive Officer and President of GoodRx, expressed confidence in the company's progress and its ability to create value for core stakeholders. She highlighted the expansion of integrated access and affordability solutions with pharmaceutical companies and the launch of a new condition-specific subscription product for erectile dysfunction.

Chris McGinnis, Chief Financial Officer and Treasurer, noted the company's solid financial performance despite facing headwinds in the larger healthcare landscape. He emphasized the strong results from the Pharma Manufacturer Solutions segment and the company's focus on strategic initiatives and operating efficiencies.

Future Outlook

For the full year 2025, GoodRx anticipates an increase in total revenue compared to 2024, with adjusted EBITDA expected to be in the range of $265 to $275 million, representing 2% to 6% growth. The company has factored in the estimated impact of the Rite Aid bankruptcy and volume reduction in one of its integrated savings programs, which are expected to result in approximately $35 to $40 million of estimated revenue loss in 2025.

SEC Filing: GoodRx Holdings, Inc. [ GDRX ] - 8-K - Aug. 06, 2025